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Although vaccination is most effective when used to prevent disease, cancer vaccine development has focused predominantly on providing therapy against established growing tumors 1 . The difficulty in developing prophylactic cancer vaccines is primarily due to the fact that tumor antigens are variations of self proteins and would probably mediate profound autoimmune complications if used in a preventive vaccine setting 2 . Here we use several mouse breast cancer models to define a prototypic strategy for prophylactic cancer vaccination. We selected a-lactalbumin as our target vaccine autoantigen because it is a breast-specific differentiation protein expressed in high amounts in the majority of human breast carcinomas [3] [4] [5] and in mammary epithelial cells only during lactation [6] [7] [8] [9] . We found that immunoreactivity against a-lactalbumin provides substantial protection and therapy against growth of autochthonous tumors in transgenic mouse models of breast cancer and against 4T1 transplantable breast tumors in BALB/c mice. Because a-lactalbumin is conditionally expressed only during lactation, vaccination-induced prophylaxis occurs without any detectable inflammation in normal nonlactating breast tissue. Thus, a-lactalbumin vaccination may provide safe and effective protection against the development of breast cancer for women in their postchild-bearing, premenopausal years, when lactation is readily avoidable and risk for developing breast cancer is high 10 .
Our overall hypothesis is that a full-strength autoimmune attack sufficient to induce organ-specific failure may provide protection and therapy against tumors derived from the targeted organ. Thus, our experimental plan involved generating a recombinant mouse mammary-specific differentiation protein antigen, determining the presence of breast autoimmunity following immunization with the generated protein and evaluating the efficacy of immunization with the breast-specific protein as both a prophylactic and therapeutic breast cancer vaccine. We generated the breast-specific α-lactalbumin cDNA from lactating mouse mammary tissue, expressed as a 6×-Histagged fusion protein and purified it by nickel-nitrilotriacetic acid affinity chromatography followed by reverse-phase HPLC to produce an endotoxin-free protein 11 (Fig. 1a) . Ten days after immunization of female SWXJ mice with recombinant mouse α-lactalbumin in complete Freund's adjuvant (CFA), lymph node cells (LNCs) showed dosedependent proliferation in recall responses to α-lactalbumin and were unresponsive to recombinant human cochlin generated in a virtually identical manner 12 (Fig. 1b) . Responsiveness to α-lactalbumin involved both CD4 + and CD8 + T cells (Fig. 1c) and showed a proinflammatory phenotype involving high production of interferon-γ (IFN-γ) and interleukin-2 (IL-2) and low production of IL-4, IL-5 and IL-10 ( Fig. 1d) .
Breast tissue from nonlactating mice immunized with α-lactalbumin never showed any inflammatory infiltration and instead consistently showed isolated individual CD3 + T cells migrating through breast parenchyma in a classic surveillance pattern (Fig. 1e) . In sharp contrast, extensive T cell infiltrates consistently occurred throughout mammary tissue of lactating mice immunized with α-lactalbumin (Fig. 1f) . Breast tissue from lactating control mice immunized with CFA alone never showed any inflammatory T cell infiltration (Fig. 1g) . Analysis of breast infiltrating T cells by flow cytometry showed high frequencies of CD3 + CD4 + T cells and CD3 + CD8 + T cells highly expressing the activation marker CD44 (Fig. 1h) . Analysis by quantitative real-time RT-PCR showed that breast tissue from lactating mice immunized with α-lactalbumin had significantly elevated expression levels of IFN-γ (P = 0.001) but not IL-10 (P > 0.10) when compared to levels expressed in breast tissue from untreated normal nonlactating or lactating mice or lactating mice immunized with CFA alone (Fig. 1i) . We subsequently found that the inflammation observed in breasts of lactating mice immunized with α-lactalbumin was T cell mediated and resulted in breast failure, which is characterized by pups showing diminished weight gain and failure to thrive, often with kwashiorkor-like signs of nutritional deficiency and runting (data not shown). This breast failure phenotype mimics that observed in α-lactalbumin-deficient mice 13 .
Our focus quickly turned to the potential use of α-lactalbumin as a breast cancer vaccine. We examined whether early immunization with α-lactalbumin could prophylactically inhibit growth of autochthonous breast tumors. MMTV-neu mice express the unactivated neu protooncogene under the regulation of the long terminal repeat of mouse mammary tumor virus (MMTV) and show a 50% incidence of spontaneous mammary tumors by 205 d of age 14 . We immunized l e t t e r s (Fig. 2b) .
We next determined whether α-lactalbumin immunization could therapeutically inhibit growth of established tumors. Although palpable tumors appear by 2-3 weeks after subcutaneous (s.c.) inoculation of BALB/c mice with 2 × 10 4 4T1 tumor cells, tumors are well established within 5 d after inoculation (Fig. 2c) . We observed significant inhibition of tumor growth (P < 0.01 in each case) when α-lactalbumin vaccination occurred at 5 d (Fig. 2d ) and 13 d (Fig. 2e) but not at 21 d (Fig. 2f) after inoculation with 4T1 tumor cells. However, the lack of tumor growth inhibition in mice immunized 21 d after inoculation may be due to the shortened 11-d observation period between the time of immunization and the time when tumors reached the maximum size mandating killing.
We also determined the effectiveness of α-lactalbumin vaccination on the growth of established autochthonous tumors. MMTV-PyVT transgenic mice constitutively express activated neu in breast tissues and develop very rapidly growing mammary tumors palpable by 5 weeks of age 15 . We observed significant inhibition (P < 0.0006) in the growth of very aggressive established autochthonous tumors in MMTV-PyVT transgenic mice vaccinated at 6 weeks of age with α-lactalbumin (Fig. 2g) . Our results indicate that α-lactalbumin vaccination provides effective protection and therapy against breast tumor growth and is particularly effective when immunization occurs before the appearance of palpable tumors.
Tumors taken 32 d after inoculation with 4T1 tumor cells and immunization with α-lactalbumin showed extensive infiltration of CD3 + T cells (Fig. 3a) . Such inflammatory infiltrates did not occur in tumors from CFA-immunized control mice (Fig. 3b) . Flow cytometry analysis of tumor infiltrating lymphocytes (TILs) showed a predominance of CD4 + (64.3%) over CD8 + (14.4%) T cells (Fig. 3c) and a type 1 proinflammatory phenotype involving high production of IFN-γ rather than IL-5 or IL-10, measured by ELISA, in response to α-lactalbumin (Fig. 3d) . Enzyme-linked immunospot (ELISPOT) analysis of TILs showed that CD4 + rather than CD8 + T cells produced the IFN-γ, as its secretion by cultured T cells was inhibited by treatment with major histocompatibility complex (MHC) class II-but not MHC class I-specific antibodies (Fig. 3e) . However, CD8 + T cells mediated 4T1-specific cytotoxicity, as death of cultured 4T1 tumor cells was inhibited by treatment of cultured α-lactalbumin-primed LNCs with antibodies specific for mouse CD8 but not CD4 (Fig. 3f) .
Transfer of α-lactalbumin-primed T cells but not primed B cells or sera induced breast failure in naive recipients (data not shown). Similarly, transfer of α-lactalbumin-primed LNCs into naive recipient BALB/c mice on the same day as inoculation with 4T1 tumors resulted in highly significant (P < 0.0001) inhibition of tumor growth (Fig. 4a) , significantly lowered (P < 0.03) the number of tumor-bearing mice (Fig. 4b) and significantly decreased (P < 0.0008) final tumor weight (Fig. 4c) . We also found that significant tumor growth inhibition occurred in naive mice receiving either CD4 + ( Fig. 4d ; P = 0.002) or CD8 + ( Fig. 4d ; P = 0.003) T cells enriched by magnetic bead separation from α-lactalbumin-primed LNCs. Overall, our data indicate that activated CD4 + and CD8 + TILs mediate the protective and therapeutic effects of α-lactalbumin vaccination on breast tumor growth.
Our study indicates that induction of autoimmune-mediated breast failure after a single immunization with α-lactalbumin provides effective breast cancer vaccination. However, the most noteworthy implication of our study is that α-lactalbumin vaccination provides prophylaxis against breast cancer in the absence of any detectable autoimmuneinduced breast inflammation. Thus, our results may serve as a rational basis for the development of a safe and effective prophylactic vaccine against human breast cancer. In a broader sense, our study defines the criteria for antigen selection in the development of any targeted prophylactic cancer vaccine: the antigen must be constitutively overexpressed in the majority of targeted tumors, expression of the target antigen in normal tissue must be conditional and the condition determining expression of the target antigen in normal tissue must be readily avoidable. The lactation-dependent milk protein, α-lactalbumin, meets these criteria for prophylactic breast cancer vaccination.
Relative to most organs, the breast is metabolically dormant until lactation occurs, at which time the milk proteins, including α-lactalbumin, are strongly induced. Thus, α-lactalbumin availability in normal nonlactating breast tissue is insufficient to target any autoimmune inflammation. This unique conditional expression of a differentiation protein provides an opportunity for prophylactic breast cancer vaccination of normal healthy women who are either willing to avoid lactation or are past their child-bearing years and at an increased risk for breast cancer. Thus, in a broader perspective, it is not difficult to envision an adult vaccination plan patterned on the childhood vaccine strategy that would provide prophylaxis against adult onset diseases including, but not limited to, breast cancer. For successful cancer vaccination, it is essential that the selected immunogen is overexpressed in the targeted tumor. Although one early study was unable to show α-lactalbumin mRNA in human breast tumors 16 , and other studies have shown that expression of α-lactalbumin protein by breast tumors may not render any substantial diagnostic or prognostic usefulness [3] [4] [5] , several reports have shown that the α-lactalbumin protein is produced in the majority of human breast malignancies at levels sufficient for detection by immunocytochemical analysis [3] [4] [5] . Moreover, recent studies involving adenoviralmediated gene delivery have shown that the promoter of the gene encoding α-lactalbumin can be used for specifically targeting human breast tumors for expression of several toxic factors, including the tumoricidal E1A transcriptional regulator 17 and the suicide genes thymidine kinase 18 and cytosine deaminase 19 . Although these studies indicate that α-lactalbumin is expressed in appreciable amounts in most human breast tumors, the ability of α-lactalbumin to be an effective target for breast cancer vaccination also depends on whether it is sufficiently immunogenic in humans. Our preliminary in vitro priming data clearly indicate that women have a substantial proinflammatory T cell repertoire available for responding to recombinant human α-lactalbumin (data not shown).
Although CD4 + T cells often may be more efficient at tumor rejection than CD8 + T cells 20 , optimal tumoricidal activity typically occurs when tumor responses involve both CD4 + and CD8 + T cells 21 . Thus, it is noteworthy that the response to α-lactalbumin involves both CD4 + and CD8 + T cells. Nevertheless, it is not likely that our current data reflect an optimized cancer vaccination strategy. Incorporation of a dendritic cell vaccine approach 22 offers the potential for in vitro shaping of the autoimmune antitumor T cell repertoire, perhaps by enhancement of the autoaggressive T helper type 17 lineage 23 or by selective co-stimulatory and/or co-inhibitory manipulation 24 . A complementary and perhaps synergistic strategy may also involve partial inhibition or ablation of FoxP3 + regulatory T cells that inhibit autoimmunity 25 . In any event, our data provide experimental support for developing safe and effective protection against breast tumors, and potentially tumors derived from other organs, by targeted vaccination against conditionally expressed, tissuespecific differentiation proteins.
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